Fresenius considers Gull options
This article was originally published in Clinica
Executive Summary
Fresenius is to consider the future of its 62%-owned subsidiary, Gull Laboratories, and has engaged investment bank Wasserstein Perella & Co to evaluate the alternatives. These include a co-operation agreement or a sale.